journal article·2023-07-22Open access

Nanoparticle-Mediated Delivery of Satraplatin to Overcome Cisplatin Drug Resistance

Xiaohan Jiang, Qiang Yang, Ruogu Qi, Lesan Yan

Abstract

Drug resistance and cancer metastasis are the major obstacles for widely used platinum-based chemotherapy. It is acknowledgement that the decreasing intracellular accumulation of anticancer drugs and increasing sulfur-binding detoxification are two major mechanisms related to drug resistance. Herein, we developed a practical and straightforward method for formulating the clinically used anticancer drug satraplatin (JM-216) with D-α-tocopheryl polyethylene glycol succinate (TPGS)-based polymers to create satraplatin-loaded nanoparticles (SatPt-NPs). The experimental results demonstrate that SatPt-NPs exhibited comparable efficacy to A2780 in treating the A2780 cisplatin-resistant ovarian cancer cell line (A2780DDP), indicating their significant potential in overcoming drug resistance. Additionally, buthionine sulfoximine (BSO) is capable of depleting intracellular glutathione (GSH), resulting in reduced detoxification. After BSO treatment, the IC50 value of SatPt-NPs changed from 0.178 to 0.133 μM, which remained relatively unchanged compared to cisplatin. This suggests that SatPt-NPs can overcome drug resistance by evading GSH detoxification. Therefore, SatPt-NPs have the ability to inhibit drug resistance in tumor cells and hold tremendous potential in cancer treatment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Metal complexes synthesis and properties · Ferrocene Chemistry and Applications · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Advanced Technology for Materials Synthesis and Processing, Biomedical Materials and Engineering Research Center of Hubei Province, Wuhan University of Technology, Wuhan 430070, China

Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Hubei Province · Fundamental Research Funds for the Central Universities · Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application, Soochow University

References (35)

Show source-provided references
1. Ovarian Cancer: An Integrated Review10.1016/j.soncn.2019.02.001 ↗
2. Recent progress in polymer-based platinum drug delivery systems10.1016/j.progpolymsci.2018.07.004 ↗
3. Turning Ineffective Transplatin into a Highly Potent Anticancer Drug via a Prodrug Strategy for Drug Delivery and Inhibiting Cisplatin Drug Resistance10.1021/acs.bioconjchem.6b00302 ↗
4. Nanoparticle delivery of sterically hindered platinum(IV) prodrugs shows 100 times higher potency than that of cisplatin upon light activation10.1039/C5CC09534D ↗
5. Delivering a photosensitive transplatin prodrug to overcome cisplatin drug resistance10.1039/C5CC03692E ↗
6. A versatile method to deliver platinum (II) drugs via thiol-ene/yne click reaction of polypeptide10.1016/j.eurpolymj.2023.112300 ↗
7. The rediscovery of platinum-based cancer therapy10.1038/s41568-020-00308-y ↗
8. Tsvetkova, D., and Ivanova, S. (2022). Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases. Molecules, 27.10.3390/molecules27082466 ↗
9. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD47310.1038/bjc.1998.59 ↗
10. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts
11. Peroxidase-like Active Nanomedicine with Dual Glutathione Depletion Property to Restore Oxaliplatin Chemosensitivity and Promote Programmed Cell Death10.1021/acsnano.1c06777 ↗
12. Clinical and pharmacokinetic evaluation of satraplatin10.1517/17425255.2012.636352 ↗
13. Satraplatin: An orally available platinum analog for the treatment of cancer10.1586/14737140.6.7.973 ↗
14. Naloxone treatment in opioid addiction: The risks and benefits10.1517/14740338.6.2.125 ↗
15. Broadening the clinical use of platinum drug-based chemotherapy with new analogues: Satraplatin and picoplatin10.1517/13543784.16.7.1009 ↗
16. Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery10.1021/ja5038269 ↗
17. Novel Metals and Metal Complexes as Platforms for Cancer Therapy10.2174/138161210791209009 ↗
18. Proteomic analysis of cisplatin- and oxaliplatin-induced phosphorylation in proteins bound to Pt-DNA adducts10.1039/d0mt00194e ↗
19. New-generation platinum drugs in the treatment of cisplatin-resistant cancers10.1517/13543784.14.8.1033 ↗
20. Relevance of Using Platinum-Containing Antitumor Compounds (A Review)10.1007/s11094-022-02702-2 ↗
21. Current status and future prospects for satraplatin, an oral platinum analogue10.1158/1078-0432.CCR-07-2176 ↗
22. Inhibition of transcription by platinum antitumor compounds10.1039/b907567d ↗
23. Nanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance10.1039/D1TB00753J ↗
24. Advances in drug delivery system for platinum agents based combination therapy
25. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs10.1021/acs.chemrev.5b00597 ↗
26. Vitamin E TPGS prodrug micelles for hydrophilic drug delivery with neuroprotective effects10.1016/j.ijpharm.2012.08.038 ↗
27. Recent Advances in the Application of Vitamin E TPGS for Drug Delivery10.7150/thno.22711 ↗
28. Depletion of cellular glutathione modulates LIF-induced JAK1-STAT3 signaling in cardiac myocytes10.1016/j.biocel.2012.08.016 ↗
29. Design and delivery of camplatin to overcome cisplatin drug resistance10.1039/C4TB01146E ↗
30. Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy10.1155/2010/430939 ↗
31. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin10.1158/1535-7163.MCT-08-0250 ↗
32. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines10.1038/sj.bjc.6600786 ↗
33. Depletion of GSH in glial cells induces neurotoxicity: Relevance to aging and degenerative neurological diseases10.1096/fj.09-149997 ↗
34. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation10.1038/sj.leu.2402179 ↗
35. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies10.1023/A:1013156407224 ↗